Editas Medicine (EDIT) Shares Outstanding (Diluted Average) (2019 - 2025)

Editas Medicine (EDIT) has 7 years of Shares Outstanding (Diluted Average) data on file, last reported at $85.9 million in Q3 2025.

• Quarterly Shares Outstanding (Diluted Average) rose 4.42% year-over-year to $85.9 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $85.9 million (up 4.42% YoY) and the FY2024 annual result came in at $82.3 million, up 8.39% from the prior year.
• Shares Outstanding (Diluted Average) improved to $85.9 million in Q3 2025 per EDIT's latest filing, from $83.7 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $85.9 million in Q3 2025 and bottomed at $66.0 million in Q1 2021.
• The 5-year median for Shares Outstanding (Diluted Average) is $71.4 million (2023), against an average of $74.5 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) climbed 0.59%; it then gained 18.88% in 2024.
• Tracing EDIT's Shares Outstanding (Diluted Average) over 5 years: stood at $67.6 million in 2021, then advanced by 1.55% to $68.7 million in 2022, then advanced by 10.63% to $76.0 million in 2023, then increased by 8.39% to $82.3 million in 2024, then gained by 4.3% to $85.9 million in 2025.
• Per Business Quant, the three latest EDIT Shares Outstanding (Diluted Average) figures stand at $85.9 million (Q3 2025), $83.7 million (Q2 2025), and $83.1 million (Q1 2025).

Peer Comparison